Cidara Therapeutics (CDTX) Given Daily Coverage Optimism Rating of 0.17

Press coverage about Cidara Therapeutics (NASDAQ:CDTX) has been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cidara Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.4039400884592 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Cidara Therapeutics (CDTX) traded up $0.15 during mid-day trading on Friday, reaching $6.95. 39,980 shares of the company’s stock were exchanged, compared to its average volume of 81,068. The company has a current ratio of 7.69, a quick ratio of 7.69 and a debt-to-equity ratio of 0.16. Cidara Therapeutics has a 12 month low of $5.60 and a 12 month high of $11.75. The firm has a market capitalization of $137.62, a PE ratio of -2.04 and a beta of 1.75.

A number of analysts have weighed in on the stock. Zacks Investment Research raised shares of Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a report on Wednesday, October 25th. Cantor Fitzgerald set a $15.00 price objective on shares of Cidara Therapeutics and gave the stock a “buy” rating in a report on Tuesday, November 28th. Finally, HC Wainwright raised their price objective on shares of Cidara Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $12.93.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Insider Buying and Selling by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply